Effects of glibenclamide and metformin on prevalence of metabolic syndrome in type 2 diabetic patients

Objectives: To investigate the effects of glibenclamide or metformin on prevalence of metabolic syndrome in type 2 diabetic patients. Methodology: One hundred type 2 diabetic patients were divided into 2 groups of equal number (Glibenclamide group and metformin group). Another group consist of 30 newly diagnosed type 2 diabetic patients were also involved as a control group. Metabolic syndrome was diagnosed according to criteria made by the US National Cholesterol Education Program Adult treatment Panel III. Waist circumference in (cm) was determined as the point midway between the costal margin and iliac crest in the mid-axillary’s line. Serum glucose concentration, serum triglycerides and HDL-Cholesterol were measured using special Kits. Results: One hundred thirty patients had metabolic syndrome in three group and the markers of metabolic syndrome were significantly lowered in the metformin group as compared with the glibenclamide group and control group. Females have metabolic syndrome greater than men. Higher age group patients were more prone to develop metabolic syndrome. Conclusion: Metformin was found to have favorable effects on the frequency of metabolic syndrome and its markers as compared with glibenclamide.